Simply Wall St.
3 Stocks Estimated To Be Trading Below Their Intrinsic Value By Up To 46.3%
📊
AI Sentiment
Positive
6/10
- Home
- DXCM
DXCM
DexCom Inc.
as of 12-09-2025 3:43pm EST
$66.36
+$0.74
+1.13%
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Chart Type:
Time Range:
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 31.7B | IPO Year: | 2005 |
| Target Price: | $87.81 | AVG Volume (30 days): | 5.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 21 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.80 | EPS Growth: | 7.75 |
| 52 Week Low/High: | $54.11 - $93.25 | Next Earning Date: | 10-30-2025 |
| Revenue: | $4,515,900,000 | Revenue Growth: | 14.21% |
| Revenue Growth (this year): | 17.41% | Revenue Growth (next year): | 12.78% |
AI-Powered DXCM Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 75.00%
75.00%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of DexCom Inc. (DXCM)
Collins Richard Alexander
Sell
Director
DXCM Nov 14, 2025
Avg Cost/Share
$59.05
Shares
2,906
Total Value
$171,599.30
Owned After
35,088
SEC Form 4
Heller Bridgette P
Sell
Director
DXCM Nov 12, 2025
Avg Cost/Share
$58.07
Shares
1,012
Total Value
$58,766.84
Owned After
27,031
SEC Form 4
Leach Jacob Steven
Buy
President & COO
DXCM Nov 10, 2025
Avg Cost/Share
$55.20
Shares
18,200
Total Value
$1,001,701.90
Owned After
329,197
Collins Richard Alexander
Sell
Director
DXCM Nov 10, 2025
Avg Cost/Share
$55.17
Shares
3,948
Total Value
$217,811.16
Owned After
35,088
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Collins Richard Alexander | DXCM | Director | Nov 14, 2025 | Sell | $59.05 | 2,906 | $171,599.30 | 35,088 | |
| Heller Bridgette P | DXCM | Director | Nov 12, 2025 | Sell | $58.07 | 1,012 | $58,766.84 | 27,031 | |
| Leach Jacob Steven | DXCM | President & COO | Nov 10, 2025 | Buy | $55.20 | 18,200 | $1,001,701.90 | 329,197 | |
| Collins Richard Alexander | DXCM | Director | Nov 10, 2025 | Sell | $55.17 | 3,948 | $217,811.16 | 35,088 |
Latest DexCom Inc. News
DXCM Breaking Stock News: Dive into DXCM Ticker-Specific Updates for Smart Investing
Simply Wall St.
Freshworks And Two More Stocks Estimated To Be Trading Below Fair Value
📈
AI Sentiment
Highly Positive
8/10
Simply Wall St.
Three Stocks Estimated To Be Trading Below Intrinsic Value In December 2025
📊
AI Sentiment
Positive
7/10
Simply Wall St.
Three Stocks That Could Be Undervalued By Market Estimates In December 2025
📊
AI Sentiment
Positive
7/10
Simply Wall St.
Three Stocks Estimated To Be Trading Below Their Intrinsic Value In December 2025
📊
AI Sentiment
Positive
7/10
Business Wire
Listening to Healthcare Professionals: Dexcom Launches New Education Offering, Dexcom Academy
📈
AI Sentiment
Highly Positive
8/10
Compare DXCM vs Leading Stocks
See how DXCM stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "DXCM DexCom Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.